Design Therapeutics(US:DSGN) Newsfilter·2025-04-21 20:01Core Insights - Design Therapeutics, Inc. is advancing its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) and will present updates at Eyecelerator @ Park City 2025 on May 2, 2025 [1] - DT-168 is a GeneTAC® small molecule eye drop targeting the CTG repeat expansion in the TCF4 gene to reduce mutant gene expression linked to FECD [2] - The Phase 1 trial results for DT-168 will be showcased, highlighting its potential to restore endothelial function in a disease with no current disease-modifying treatments [3] Company Overview - Design Therapeutics is a clinical-stage biotechnology company focused on developing GeneTAC® therapies aimed at addressing serious degenerative genetic diseases [4] - The company is also developing DT-216P2 for Friedreich ataxia and has programs targeting myotonic dystrophy type-1 and Huntington's disease [4]